Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Canagliflozin

FDA-approved product (tablet, oral), marketed as Canagliflozin, Invokana.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Canagliflozin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sodium-glucose co-transporter 2 (sglt2) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis45.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Canagliflozin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Canagliflozin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • CANagliflozin In DIALysis Patients

    NCT07527390 · start 2026-06-01

    Registered record
    Registry ID
    NCT07527390
    Conditions
    Dialysis; Chronic Kidney Disease (Stages 4 and 5)
    Interventions
    Invokana 300 mg and 100 mg tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-06-01
    Completion
    2027-01-30
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDialysis; Chronic Kidney Disease (Stages 4 and 5)
    InterventionInvokana 300 mg and 100 mg tablet
    PhasePhase 4
    Registry statusNot yet recruiting

  • Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis

    NCT06913647 · start 2026-02-01

    Registered record
    Registry ID
    NCT06913647
    Conditions
    ESRD; CKD (Chronic Kidney Disease) Stage 5D
    Interventions
    Canagliflozin 300 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-02-01
    Completion
    2028-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionESRD; CKD (Chronic Kidney Disease) Stage 5D
    InterventionCanagliflozin 300 MG
    PhasePhase 2
    Registry statusRecruiting

  • Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.

    NCT07391267 · start 2026-02-01

    Registered record
    Registry ID
    NCT07391267
    Conditions
    Chronic Kidney Diseases; MAFLD
    Interventions
    Semaglutide Oral Tablet; Placebo; Standard medical treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-02-01
    Completion
    2028-12-31
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Diseases; MAFLD
    InterventionSemaglutide Oral Tablet; Placebo; Standard medical treatment
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

    NCT07325435 · start 2024-12-21

    Registered record
    Registry ID
    NCT07325435
    Conditions
    Type 2 Diabetes (T2DM)
    Interventions
    SGLT-2 inhibitor; GLP1-RA
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2024-12-21
    Completion
    2028-06-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes (T2DM)
    InterventionSGLT-2 inhibitor; GLP1-RA
    PhasePhase 4
    Registry statusActive not recruiting

  • The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease

    NCT06528405 · start 2024-11-21

    Registered record
    Registry ID
    NCT06528405
    Conditions
    Acute Kidney Injury
    Interventions
    dapagliflozin; Other anti-diabetic drug or no anti-diabetic drug; empagliflozin; canagliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-11-21
    Completion
    2027-12
    Enrolment
    264

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Kidney Injury
    Interventiondapagliflozin; Other anti-diabetic drug or no anti-diabetic drug; empagliflozin; canagliflozin
    PhasePhase 2
    Registry statusRecruiting

  • Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment

    NCT07711171 · start 2024-08-19

    Registered record
    Registry ID
    NCT07711171
    Conditions
    Type 2 Diabetes Mellitus; Cognitive Impairment
    Interventions
    Canagliflozin group; Sitagliptin; Acarbose
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-08-19
    Completion
    2026-10-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus; Cognitive Impairment
    InterventionCanagliflozin group; Sitagliptin; Acarbose
    PhasePhase 4
    Registry statusRecruiting

  • Canagliflozin in Advanced Renal Disease With MRI Endpoints

    NCT06182839 · start 2024-05-01

    Registered record
    Registry ID
    NCT06182839
    Conditions
    ESRD, CKD Stage 4, CKD Stage 5
    Interventions
    Canagliflozin 300Mg Tab; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-05-01
    Completion
    2029-03-30
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionESRD, CKD Stage 4, CKD Stage 5
    InterventionCanagliflozin 300Mg Tab; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Treatment of Patients With Diabetic Kidney Disease

    NCT06187493 · start 2024-01-01

    Registered record
    Registry ID
    NCT06187493
    Conditions
    Diabetic Kidney Disease
    Interventions
    lisinopril, enalapril; dapagliflozin, empagliflozin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-01-01
    Completion
    2025-12-31
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Kidney Disease
    Interventionlisinopril, enalapril; dapagliflozin, empagliflozin
    PhaseNot applicable
    Registry statusUnknown

  • Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

    NCT07309094 · start 2023-09-15

    Registered record
    Registry ID
    NCT07309094
    Conditions
    Chronic Kidney Disease stage3; Chronic Kidney Disease stage4; Chronic Kidney Disease Stage 1; Chronic Kidney Disease Stage 2; Obesity; Diabetes Mellitus, Type 2
    Interventions
    GLP-1 receptor agonist; SGLT2 inhibitor; Tirzepatide; Other drugs
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2023-09-15
    Completion
    2028-12-31
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease stage3; Chronic Kidney Disease stage4; Chronic Kidney Disease Stage 1; Chronic Kidney Disease Stage 2 +2 more
    InterventionGLP-1 receptor agonist; SGLT2 inhibitor; Tirzepatide; Other drugs
    PhaseNot recorded
    Registry statusRecruiting

  • Canagliflozin in Patients With Acute Decompansted Heart Failure

    NCT05364190 · start 2022-06-04

    Registered record
    Registry ID
    NCT05364190
    Conditions
    Chronic Heart Failure; Acute Heart Failure; Diabetes Mellitus
    Interventions
    Canagliflozin; Empagliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-06-04
    Completion
    2024-03-01
    Enrolment
    142

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Heart Failure; Acute Heart Failure; Diabetes Mellitus
    InterventionCanagliflozin; Empagliflozin
    PhasePhase 3
    Registry statusCompleted

  • Comparing the Efficacy of Mulberry Twig Alkaloid Tablet and Canagliflozin in Patients With Type 2 Diabetes

    NCT05856578 · start 2022-03-15

    Registered record
    Registry ID
    NCT05856578
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Mulberry Twig Alkaloid Tablet; Canagliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-03-15
    Completion
    2023-12-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionMulberry Twig Alkaloid Tablet; Canagliflozin
    PhasePhase 4
    Registry statusUnknown

  • Canagliflozin and Myocardial Fibrosis

    NCT05367063 · start 2022-01-05

    Registered record
    Registry ID
    NCT05367063
    Conditions
    Type 2 Diabetes; Cardiovascular Risk
    Interventions
    Canagliflozin 100mg or Sitagliptin 100mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-01-05
    Completion
    2025-03-20
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes; Cardiovascular Risk
    InterventionCanagliflozin 100mg or Sitagliptin 100mg
    PhasePhase 4
    Registry statusCompleted

  • The Efficacy of SGLT-2 Inhibitor in Patients With CAD and DM Undergoing PCI.

    NCT05333159 · start 2021-09-01

    Registered record
    Registry ID
    NCT05333159
    Conditions
    Coronary Artery Disease; Diabete Mellitus
    Interventions
    SGLT2 inhibitor
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-09-01
    Completion
    2024-12-30
    Enrolment
    1,424

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Diabete Mellitus
    InterventionSGLT2 inhibitor
    PhaseNot recorded
    Registry statusUnknown

  • Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)

    NCT04304261 · start 2021-07-01

    Registered record
    Registry ID
    NCT04304261
    Conditions
    Diabetes Mellitus, Type 2; Cognitive Functions Confusion
    Interventions
    Canagliflozin; Sitagliptin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-07-01
    Completion
    2024-04-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2; Cognitive Functions Confusion
    InterventionCanagliflozin; Sitagliptin
    PhasePhase 3
    Registry statusCompleted

  • A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

    NCT04073680 · start 2020-09-01

    Registered record
    Registry ID
    NCT04073680
    Conditions
    Breast Cancer; Endometrial Cancer; Lung Cancer; Colo-rectal Cancer; Head and Neck Cancer
    Interventions
    Serabelisib; Canagliflozin 300mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2020-09-01
    Completion
    2021-12-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Endometrial Cancer; Lung Cancer; Colo-rectal Cancer +1 more
    InterventionSerabelisib; Canagliflozin 300mg
    PhasePhase 1 / Phase 2
    Registry statusUnknown